TRULICITY 1.5 MG Options
The trial achieved equally its Most important endpoints, with semaglutide 2.4 mg demonstrating statistically substantial and top-quality improvements in liver fibrosis without having worsening of steatohepatitis, as well as resolution of steatohepatitis without having worsening of liver fibrosis in people with MASH compared to placebo.oneSemaglutid